BNTA - 10mM in DMSO , CAS No.685119-25-9

CAS: 685119-25-9 Cat. No.: B655155 Formule: C₁₇H₁₁BrClNO₃S₂ Poids moléculaire: 456.76 PubChem CID: 2819453

QUALITÉ & PURETÉ 10mM in DMSO

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Vue d’ensemble

BNTA, a potent extracellular matrix (ECM) modulator, facilitates cartilage structural molecule synthesis on chondrocytes by activating superoxide dismutase 3 (SOD3). BNTA shows a promising potential for osteoarthritis alleviation by modulating cartilage generation.

In Vitro

BNTA (0.01-10 μM; 1-7 d) does not decrease cell viability of human osteoarthritis chondrocytes and rat primary chondrocytes. BNTA (0.1 μM; 2 d) increases SOX9 protein markedly. BNTA (0.1 μM; 2 d) remarkably increases the COL2A1 and SOX9 protein levels in IL1β-induced rat OA chondrocytes. BNTA (10 μM; 5 d) increases proteoglycan staining in ATDC5 cells. BNTA (0.01-10 μM; 6 h) upregulates the expression levels of ECM-related genes COL2A1 , ACAN , proteoglycan 4 ( PRG4 ), and SRY-box 9 ( SOX9 ) in human OA chondrocytes. BNTA (0.01-10 μM; 6 h) increases Col2a1 , Acan , Prg4 , and Sox9 mRNA levels, with maximum effects around 0.1 μM in IL1β-induced rat OA chondrocytes. BNTA (0.01-1 μM; 2 or 3 w) enhances anabolism and inhibited inflammatory response in osteoarthritis cartilage explants. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: Human OA chondrocytes Concentration: 0.01, 0.1, 1, 10 μM Incubation Time: 1, 3, 5, 7 d Result: No toxicity was observed. Western Blot AnalysisCell Line: Human OA chondrocytes Concentration: 0.1 μM Incubation Time: 2 d Result: Elevated SOX9 protein compared with vehicle.

In Vivo

BNTA (0.015-1.5 mg/kg; intra-articular injection; twice a week for 4 and 8 weeks) could attenuate OA progression developed after anterior cruciate ligament transection (ACLT) in rats . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male SD rats weighing 80 g are induced by ACLT Dosage: 0.015, 0.15, 1.5 mg/kg Administration: Intra-articular injection; twice a week for 4 and 8 weeks Result: Attenuated post-traumatic osteoarthritis development after intra-articular injection for 4 and 8 weeks and was well tolerated.

Spécifications

Spécifications et pureté

10mM in DMSO

Mécanismes biochimiques et physiologiques

BNTA, a potent extracellular matrix (ECM) modulator, facilitates cartilage structural molecule synthesis on chondrocytes by activating superoxide dismutase 3 (SOD3) . BNTA shows a promising potential for osteoarthritis alleviation by modulating cartilage

Conditions de stockage de stockage

Store at -80°C

Expédié en

Dry ice packs + Cold packs

Ce produit nécessite l'expédition en chaîne froide. Les services terrestres et autres services économiques ne sont pas disponibles.

Noms et identifiants

Isomères SMILES

C1=CC=C(C=C1)S(=O)(=O)C2=CSC(=C2NC(=O)C3=CC=CC=C3Cl)Br

PubChem CID

2819453

Poids moléculaire

456.76